Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
← catalyst calendarNCT04279847 · readout in 254 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
140actual
Sites
48
Countries
Canada, China, Finland +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-23 | actual | When the study began enrolling |
| Primary completion | 2027-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2020-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Myelofibrosis
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome
- Myeloproliferative Neoplasm
- Relapsed or Refractory Primary Myelofibrosis
- Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
- ET (Essential Thrombocythemia)
Interventions
- Drug: INCB057643
- Drug: Ruxolitinib
Primary outcome
what the primary-completion date above is the date OFNumber of treatment-emergent adverse events
measured Up to approximately 9 months
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed